Sfoglia per AUTORE
CAMERINI A
Collezione AOU Novara
Items : 2
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1?50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. in Journal for immunotherapy of cancer / J Immunother Cancer. 2025 Feb 4;13(2):e010674. doi: 10.1136/jitc-2024-010674.
2025
AOU San Luigi di Orbassano
AOU Novara
AOU San Luigi di Orbassano
AOU Novara
Wakelee H; Garassino M; Peters S; Takada K; Naqash AR; Torri V; Hejleh TA; Ferrara R; Aerts JGJV; Aboubakar Nana F; Dingemans AM; Biello F; Rogado J; Moliner L; Beninato T; Lo Russo G; Servetto A; Mezquita L; Gorría T; Minuti G; Bennati C; Tonini G; Cortinovis DL; Agustoni F; Majem M; Baena J; Macerelli M; Monnet I; O'Reilly D; et alii...
Clinical and radiological features driving patient selection for antiangiogenic therapy in non-small cell lung cancer (NSCLC). in Cancer imaging : the official publication of the International Cancer Imaging Society / Cancer Imaging. 2016 Dec 28;16(1):44. doi: 10.1186/s40644-016-0102-4.
2016
AOU Novara
AOU Novara
Gridelli C; Camerini A; Pappagallo G; Pennella A; Anzidei M; Bellomi M; Buosi R; Grasso RF;